These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33372541)

  • 1. Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Otsuka T; Origasa H;
    J Am Heart Assoc; 2021 Jan; 10(1):e018585. PubMed ID: 33372541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Otsuka T; Tomita H; Origasa H;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27620886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation: A subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Int J Cardiol; 2020 Mar; 302():81-87. PubMed ID: 31785960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation　- Results of the J-RHYTHM Registry 2.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    Circ J; 2016; 80(4):843-51. PubMed ID: 27001190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):59-68. PubMed ID: 28950373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Systolic Blood Pressure Time in Target Range on Adverse Events in Patients With Nonvalvular Atrial Fibrillation (from the J-RHYTHM Registry).
    Kodani E; Inoue H; Atarashi H; Okumura K; Suzuki S; Yamashita T; Origasa H;
    Am J Cardiol; 2022 Oct; 180():52-58. PubMed ID: 35909018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcomes in elderly patients with non-valvular atrial fibrillation and high bleeding risk: subanalysis of the J-RHYTHM Registry.
    Kodani E; Inoue H; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Heart Vessels; 2024 Apr; 39(4):330-339. PubMed ID: 38103100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management).
    Proietti M; Romiti GF; Olshansky B; Lip GYH
    Hypertension; 2017 Nov; 70(5):949-958. PubMed ID: 28974568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry.
    Okumura K; Inoue H; Atarashi H; Yamashita T; Tomita H; Origasa H;
    Circ J; 2014; 78(7):1593-9. PubMed ID: 24759791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home Blood Pressure Can Predict the Risk for Stroke/Bleeding Events in Elderly Patients With Nonvalvular Atrial Fibrillation From the ANAFIE Registry.
    Kario K; Hasebe N; Okumura K; Yamashita T; Akao M; Atarashi H; Ikeda T; Koretsune Y; Shimizu W; Suzuki S; Tsutsui H; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Morishima Y; Takita A; Inoue H
    Hypertension; 2022 Dec; 79(12):2696-2705. PubMed ID: 36259381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study.
    Lau WCY; Douglas IJ; Wong ICK; Smeeth L; Lip GYH; Leung WK; Siu CW; Cheung BMY; Mok MTC; Chan EW
    Heart Rhythm; 2020 Jan; 17(1):33-40. PubMed ID: 31377423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus.
    Kumagai N; Nusser JA; Inoue H; Okumura K; Yamashita T; Kubo T; Kitaoka H; Origasa H; Atarashi H;
    Am J Cardiol; 2017 Jul; 120(2):230-235. PubMed ID: 28532776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Clementy N; Haguenoer K; Fauchier L; Lip GY
    Am J Med; 2014 Oct; 127(10):972-8. PubMed ID: 24929021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.
    Darkow T; Vanderplas AM; Lew KH; Kim J; Hauch O
    Curr Med Res Opin; 2005 Oct; 21(10):1583-94. PubMed ID: 16238898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
    Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.